Porcine β-defensin 2 attenuates inflammation and mucosal lesions in dextran sodium sulfate-induced colitis

Journal of Immunology

Volumn 194, Issue 4, 2015, Pages 1882-1893

  Han, Feifei ^a,b   Zhang, Haiwen ^a   Xia, Xi ^a   Xiong, Haitao ^a   Song, Deguang ^a   Zong, Xin ^a   Wang, Yizhen ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG GONGSHANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CLAUDIN 1; CYCLOOXYGENASE 2; EOSINOPHIL PEROXIDASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; MUCIN; MUCIN 1; MUCIN 2; MYELOPEROXIDASE; PORCINE BETA DEFENSIN 2; PROTEIN ZO1; PROTEIN ZO2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BETA DEFENSIN; DEXTRAN SULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; COLITIS; COLON MUCOSA; CONTROLLED STUDY; DRUG MECHANISM; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; TIGHT JUNCTION; ANIMAL; C57BL MOUSE; CACO 2 CELL LINE; DISEASE MODEL; DRUG EFFECTS; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; INFLAMMATION; INTESTINE MUCOSA; METABOLISM; NICK END LABELING; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SWINE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BETA-DEFENSINS; BLOTTING, WESTERN; CACO-2 CELLS; COLITIS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INFLAMMATION; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED C57BL; NF-KAPPA B; REAL-TIME POLYMERASE CHAIN REACTION; SWINE;

EID: 84922553140     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402300     Document Type: Article

References (86)

1. Xavier, R. J., and D. K. Podolsky. 2007. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448: 427-434.
2. Gordon, J. N., K. M. Pickard, A. Di Sabatino, J. D. Prothero, S. L. Pender, P. M. Goggin, and T. T. MacDonald. 2008. Matrix metalloproteinase-3 production by gut IgG plasma cells in chronic inflammatory bowel disease. Inflamm. Bowel Dis. 14: 195-203.
3. Monteleone, G., R. Caruso, D. Fina, I. Peluso, V. Gioia, C. Stolfi, M. C. Fantini, F Caprioli, R. Tersigni, L. Alessandroni, et al. 2006. Control of matrix metal-loproteinase production in human intestinal fibroblasts by interleukin 21. Gut 55: 1774-1780.
4. Matricon, J., N. Barnich, and D. Ardid. 2010. Immunopathogenesis of inflammatory bowel disease. Self Nonself 1: 299-309.
5. Gibson, P. R. 2004. Increased gut permeability in Crohn's disease: is TNF the link? Gut 53: 1724-1725.
6. Turner, J. R. 2009. Intestinal mucosal barrier function in health and disease. Nat. Rev. Immunol. 9: 799-809.
7. McGuckin, M. A., R. Eri, L. A. Simms, T. H. Florin, and G. Radford-Smith. 2009. Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm. Bowel Dis. 15: 100-113.
8. Hering, N. A, and J. D. Schulzke. 2009. Therapeutic options to modulate barrier defects in inflammatory bowel disease. Dig. Dis. 27: 450-454.
9. Koch, S., and A. Nusrat. 2009. Dynamic regulation of epithelial cell fate and barrier function by intercellular junctions. Ann. N. Y. Acad. Sci. 1165: 220-227.
10. Diesing, A. K., C. Nossol, P. Panther, N. Walk, A. Post, J. Kluess, P. Kreutzmann, S. Dänicke, H. J. Rothkötter, and S. Kahlert. 2011. Mycotoxin deoxynivalenol (DON) mediates biphasic cellular response in intestinal porcine epithelial cell lines IPEC-1 and IPEC-J2. Toxicol. Lett. 200: 8-18.
11. Severson, E. A., M. Kwon, R. S. Hilgarth, C. A. Parkos, and A. Nusrat. 2010. Glycogen synthase kinase 3 (GSK-3) influences epithelial barrier function by regulating occludin, claudin-1 and E-cadherin expression. Biochem. Biophys. Res. Commun. 397: 592-597.
12. Ewert, P., S. Aguilera, C. Alliende, Y. J. Kwon, A. Albornoz, C. Molina, U. Urzúa, A F Quest, N. Olea, P. Pérez, et al. 2010. Disruption of tight junction structure in salivary glands from Sjogren's syndrome patients is linked to proinflammatory cytokine exposure. Arthritis Rheum. 62: 1280-1289.
13. Ramakrishna, B. S. 2009. Probiotic-induced changes in the intestinal epithelium: implications in gastrointestinal disease. Trop. Gastroenterol. 30: 76-85.
14. Fillon, S., Z. D. Robinson, S. P. Colgan, and G. T. Furuta. 2009. Epithelial function in eosinophilic gastrointestinal diseases. Immunol. Allergy Clin. North Am. 29: 171-178, xii-xiii.
15. Beutler, B. 2004. Innate immunity: an overview. Mol. Immunol. 40: 845-859.
16. Wehkamp, J., M. Schmid, and E. F. Stange. 2007. Defensins and other antimicrobial peptides in inflammatory bowel disease. Curr. Opin. Gastroenterol. 23: 370-378.
17. Subramanian, S., B. J. Campbell, and J. M. Rhodes. 2006. Bacteria in the pathogenesis of inflammatory bowel disease. Curr. Opin. Infect. Dis. 19: 475-484.
18. Salzman, N. H., M. A. Underwood, and C. L. Bevins. 2007. Paneth cells, defensins, and the commensal microbiota: a hypothesis on intimate interplay at the intestinal mucosa. Semin. Immunol. 19: 70-83.
19. Wehkamp, J., K. Fellermann, K. R. Herrlinger, S. Baxmann, K Schmidt, B. Schwind, M. Duchrow, C. Wohlschläger, A. C. Feller, and E. F Stange. 2002. Human β-defensin 2 but not β-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 14: 745-752.
20. Ramasundara, M., S. T Leach, D. A. Lemberg, and A. S. Day. 2009. Defensins and inflammation: the role of defensins in inflammatory bowel disease. J. Gastroenterol. Hepatol. 24: 202-208.
21. Semple, F, S. Webb, H. N. Li, H. B. Patel, M. Perretti, I. J. Jackson, M. Gray, D. J. Davidson, and J. R. Dorin. 2010. Human β-defensin 3 has immunosuppressive activity in vitro and in vivo. Eur. J. Immunol. 40: 1073-1078.
22. Badr, G. 2013. Camel whey protein enhances diabetic wound healing in a streptozotocin-induced diabetic mouse model: the critical role of β-defensin-1, -2 and -3. Lipids Health Dis. 12: 46.
23. Gan, Y., X. Cui, T. Ma, Y Liu, A. Li, and M. Huang. 2014. Paeoniflorin upre-gulates β-defensin-2 expression in human bronchial epithelial cell through the p38 MAPK, ERK, and NF-ΚB signaling pathways. Inflammation 5: 1468-1475.
24. Rivas-Santiago, B., V. Trujillo, A. Montoya, I. Gonzalez-Curiel, J. Castaneda-Delgado, A. Cardenas, K. Rincon, M. L. Hernandez, and R. Hernández-Pando. 2012. Expression of antimicrobial peptides in diabetic foot ulcer. J. Dermatol. Sci. 65: 19-26.
25. Niu, X., T Fan, W. Li, H. Huang, Y Zhang, and W. Xing. 2013. Protective effect of sanguinarine against acetic acid-induced ulcerative colitis in mice. Toxicol. Appl. Pharmacol. 267: 256-265.
26. Koon, H. W., D. Zhao, Y. Zhan, M. P. Moyer, and C. Pothoulakis. 2007. Substance P mediates antiapoptotic responses in human colonocytes by Akt activation. Proc. Natl. Acad. Sci. USA 104: 2013-2018.
27. Cooper, H. S., S. N. Murfhy, R. S. Shah, and D. J. Sedergran. 1993. Clinico-pathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest. 69: 238-249.
28. Toyoda, T., T. Tsukamoto, M. Yamamoto, H. Ban, N. Saito, S. Takasu, L. Shi, A. Saito, S. Ito, Y. Yamamura, et al. 2013. Gene expression analysis of a Helicobacter pylori-infected and high-salt diet-treated mouse gastric tumor model: identification of CD177 as a novel prognostic factor in patients with gastric cancer. BMC Gastroenterol. 13: 122.
29. Gavrieli, Y, Y Sherman, and S. A. Ben-Sasson. 1992. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 119:493-501.
30. Werner, U., and I. Szelenyi. 1992. Measurement of MPO activity as model for detection of granulocyte infiltration in different tissues. Agents Actions 36: C101-C103.
31. Yu, T., J. Lee, Y G Lee, S. E. Byeon, M. H. Kim, E. H. Sohn, Y. J. Lee, S. G. Lee, and J. Y. Cho. 2010. In vitro and in vivo anti-inflammatory effects of ethanol extract from Acer tegmentosum. J. Ethnopharmacol. 128: 139-147.
32. -ΔΔC(T) method. Methods 25: 402-408.
33. Brown, S. J., and L. Mayer. 2007. The immune response in inflammatory bowel disease. Am. J. Gastroenterol. 102: 2058-2069.
34. Vieira, E. L., A. J. Leonel, A. P. Sad, N. R. Beltrão, T. F Costa, T. M. Ferreira, A. C. Gomes-Santos, A. M. Faria, M. C. Peluzio, D. C. Cara, and J. I. Alvarez-Leite. 2012. Oral administration of sodium butyrate attenuates inflammation and mucosal lesion in experimental acute ulcerative colitis. J. Nutr. Biochem. 23: 430-436.
35. Koon, H. W., D. Q. Shih, J. Chen, K. Bakirtzi, T. C. Hing, I. Law, S. Ho, R. Ichikawa, D. Zhao, H. Xu, et al. 2011. Cathelicidin signaling via the Tolllike receptor protects against colitis in mice. Gastroenterology 141: 1852-1863. e1-3.
36. Tai, E. K., W. K. Wu, H. P. Wong, E. K. Lam, L. Yu, and C. H. Cho. 2007. A new role for cathelicidin in ulcerative colitis in mice. Exp. Biol. Med. (Maywood) 232: 799-808.
37. Schlusselhuber, M., R. Torelli, C. Martini, M. Leippe, V. Cattoir, R. Leclercq, C. Laugier, J. Grötzinger, M. Sanguinetti, and J. Cauchard. 2013. The equine antimicrobial peptide eCATHl is effective against the facultative intracellular pathogen Rhodococcus equi in mice. Antimicrob. Agents Chemother. 57: 4615-4621.
38. Rivas-Santiago, B., C. E. Rivas Santiago, J. E. Castaneda-Delgado, J. C. León-Contreras, R. E. Hancock, and R. Hernandez-Pando. 2013. Activity of LL-37, CRAMP and antimicrobial peptide-derived compounds E2, E6 and CP26 against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 41: 143-148.
39. Jiang, Y, D. Yang, W. Li, B. Wang, Z. Jiang, and M. Li. 2012. Antiviral activity of recombinant mouse β-defensin 3 against influenza A virus in vitro and in vivo. Antivir. Chem. Chemother. 22: 255-262.
40. Xiong, Y Q., W. A. Hady, A. Deslandes, A. Rey, L. Fraisse, H. H. Kristensen, M. R. Yeaman, and A. S. Bayer. 2011. Efficacy of NZ2114, a novel plectasin-derived cationic antimicrobial peptide antibiotic, in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 55: 5325-5330.
41. Noto, P. B., G. Abbadessa, M. Cassone, G D. Mateo, A. Agelan, J. D. Wade, D. Szabo, B. Kocsis, K. Nagy, F Rozgonyi, and L. Otvos, Jr. 2008. Alternative stabilities of a proline-rich antibacterial peptide in vitro and in vivo. Protein Sci. 17: 1249-1255.
42. Zhang, H., G. Porro, N. Orzech, B. Mullen, M. Liu, and A. S. Slutsky. 2001. Neutrophil defensins mediate acute inflammatory response and lung dysfunction in dose-related fashion. Am. J. Physiol. Lung Cell. Mol. Physiol. 280: L947-L954.
43. Dieleman, L. A., B. U. Ridwan, G. S. Tennyson, K. W. Beagley, R. P. Bucy, and C. O. Elson. 1994. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 107: 1643-1652.
44. Okayasu, I., S. Hatakeyama, M. Yamada, T Ohkusa, Y Inagaki, and R. Nakaya. 1990. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98: 694-702.
45. Okayasu, I. 2012. Development of ulcerative colitis and its associated colorectal neoplasia as a model of the organ-specific chronic inflammation-carcinoma sequence. Pathol. Int. 62: 368-380.
46. Podolsky, D. K. 2002. Inflammatory bowel disease. N. Engl. J. Med. 347: 417-429.
47. Hill, D. A., and D. Artis. 2010. Intestinal bacteria and the regulation of immune cell homeostasis. Annu. Rev. Immunol. 28: 623-667.
48. Wehkamp, J., J. Harder, M. Weichenthal, O. Mueller, K. R. Herrlinger, K. Fellermann, J. M. Schroeder, and E. F Stange. 2003. Inducible and constitutive β-defensins are differentially expressed in Crohn's disease and ulcerative colitis. Inflamm. Bowel Dis. 9: 215-223.
49. Lehrer, R. I. 2004. Primate defensins. Nat. Rev. Microbiol. 2: 727-738.
50. Yang, D., O. Chertov, S. N. Bykovskaia, Q. Chen, M. J. Buffo, J. Shogan, M. Anderson, J. M. Schröder, J. M. Wang, O. M. Howard, and J. J. Oppenheim. 1999. β-Defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 286: 525-528.
51. McDermott, A. M. 2004. Defensins and other antimicrobial peptides at the ocular surface. Ocul. Surf. 2: 229-247.
52. Bals, R., M. J. Goldman, and J. M. Wilson. 1998. Mouse β-defensin 1 is a salt-sensitive antimicrobial peptide present in epithelia of the lung and urogenital tract. Infect. Immun. 66: 1225-1232.
53. Hussain, T., N. Nasreen, Y Lai, B. F. Beilew, V. B. Antony, and K. A. Mohammed. 2008. Innate immune responses in murine pleural mesothelial cells: Toll-like receptor-2 dependent induction of β-defensin-2 by staphylococcal peptidoglycan. Am. J. Physiol. Lung Cell. Mol. Physiol. 295: L461-L470.
54. Garcia, J. R., F Jaumann, S. Schulz, A. Krause, J. Rodriguez-Jimenez, U. Forssmann, K. Adermann, E. Klüver, C. Vogelmeier, D. Becker, et al. 2001. Identification of a novel, multifunctional β-defensin (human β-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattraction. Cell Tissue Res. 306: 257-264.
55. Sang, Y, A. A. Patil, G. Zhang, C. R. Ross, and F. Blecha. 2006. Bioinformatic and expression analysis of novel porcine β-defensins. Mamm. Genome 17: 332-339.
56. Veldhuizen, E. J., A. van Dijk, M. H. Tersteeg, S. I. Kalkhove, J. van der Meulen, T. A. Niewold, and H. R Haagsman. 2007. Expression of β-defensins pBD-1 and pBD-2 along the small intestinal tract of the pig: lack of upregulation in vivo upon Salmonella typhimurium infection. Mol. Immunol. 44: 276-283.
57. Oswald, I. P. 2006. Role of intestinal epithelial cells in the innate immune defence of the pig intestine. Vet. Res. 37: 359-368.
58. Park, E. J., A. B. Thomson, and M. T. Clandinin. 2010. Protection of intestinal occludin tight junction protein by dietary gangliosides in lipopolysaccharide-induced acute inflammation. J. Pediatr. Gastroenterol. Nutr. 50: 321-328.
59. Chichlowski, M., G. S. Westwood, S. N. Abraham, and L. P. Hale. 2010. Role of mast cells in inflammatory bowel disease and inflammation-associated colorectal neoplasia in IL-10-deficient mice. PLoS ONE 5: e12220.
60. McCall, I. C, A. Betanzos, D. A. Weber, P. Nava, G. W. Miller, and C. A. Parkos. 2009. Effects of phenol on barrier function of a human intestinal epithelial cell line correlate with altered tight junction protein localization. Toxicol. Appl. Pharmacol. 241: 61-70.
61. Suzuki, T., N. Yoshinaga, and S. Tanabe. 2011. Interleukin-6 (IL-6) regulates claudin-2 expression and tight junction permeability in intestinal epithelium. J. Biol. Chem. 286: 31263-31271.
62. Oshitani, N., K. Watanabe, S. Nakamura, Y Fujiwara, K. Higuchi, and T. Arakawa. 2005. Dislocation of tight junction proteins without F-actin disruption in inactive Crohn's disease. Int. J. Mol. Med. 15: 407-410.
63. Qin, H., Z. Zhang, X. Hang, and Y Jiang. 2009. L. plantarum prevents entero-invasive Escherichia coli-induced tight junction proteins changes in intestinal epithelial cells. BMC Microbiol. 9: 63.
64. Wehkamp, J., H. Chu, B. Shen, R. W. Feathers, R. J. Kays, S. K. Lee, and C. L. Bevins. 2006. Paneth cell antimicrobial peptides: topographical distribution and quantification in human gastrointestinal tissues. FEBS Lett. 580: 5344-5350.
65. Talero, E., S. Sánchez-Fidalgo, C. A. de la Lastra, M. Illanes, J. R. Calvo, and V. Motilva. 2008. Acute and chronic responses associated with adrenomedullin administration in experimental colitis. Peptides 29: 2001-2012.
66. Buell, M. G., and M. C. Berin. 1994. Neutrophil-independence of the initiation of colonic injury. Comparison of results from three models of experimental colitis in the rat. Dig. Dis. Sci. 39: 2575-2588.
67. Rachmilewitz, D., P. L. Simon, L. W. Schwartz, D. E. Griswold, J. D. Fondacaro, and M. A. Wasserman. 1989. Inflammatory mediators of experimental colitis in rats. Gastroenterology 97: 326-337.
68. Choudhary, S., A. Keshavarzian, S. Yong, M. Wade, S. Bocckino, B. J. Day, and A. Banan. 2001. Novel antioxidants zolimid and AEOL11201 ameliorate colitis in rats. Dig. Dis. Sci. 46: 2222-2230.
69. Liu, E. S., and C. H. Cho. 2000. Relationship between ethanol-induced gastritis and gastric ulcer formation in rats. Digestion 62: 232-239.
70. Atreya, R., J. Mudter, S. Finotto, J. Müllberg, T. Jostock, S. Wirtz, M. Schütz, B. Bartsch, M. Holtmann, C. Becker, et al. 2000. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat. Med. 6: 583-588.
71. Hayashi, T., T. Ishida, S. Motoya, F. Itoh, T. Takahashi, Y Hinoda, and K. Imai. 2001. Mucins and immune reactions to mucins in ulcerative colitis. Digestion 63 (Suppl. 1): 28-31.
72. Van der Sluis, M., B. A. De Koning, A. C. De Bruijn, A. Velcich, J. P. Meijerink, J. B. Van Goudoever, H. A. Büller, J. Dekker, I. Van Seuningen, I. B. Renes, and A. W. Einerhand. 2006. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 131: 117-129.
73. Pullan, R. D., G. A. Thomas, M. Rhodes, R. G. Newcombe, G. T. Williams, A. Allen, and J. Rhodes. 1994. Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis. Gut 35: 353-359.
74. Tytgat, K M., J. W. van der Wal, A. W. Einerhand, H. A. Büller, and J. Dekker. 1996. Quantitative analysis of MUC2 synthesis in ulcerative colitis. Biochem. Biophys. Res. Commun. TIA'. 397-405.
75. Hibi, T., N. Inoue, H. Ogata, and M. Naganuma. 2003. Introduction and overview: recent advances in the immunotherapy of inflammatory bowel disease. J. Gastroenterol. 38(Suppl. 15): 36-42.
76. van Deventer, S. J. 1997. [Immunology in medical practice. IV Inflammatory bowel diseases: pathogenic starting points for specific therapy]. Ned. Tijdschr. Geneeskd. 141: 1956-1959.
77. Hyams, J. S., T Lerer, A. Griffiths, M. Pfefferkorn, S. Kugathasan, J. Evans, A. Otley, R. Carvalho, D. Mack, A. Bousvaros, et al; Pediatric Inflammatory Bowel Disease Collaborative Research Group. 2009. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm. Bowel Dis. 15: 816-822.
78. Polgár, A., M. Brózik, S. Tóth, M. Holub, K. Hegyi, A. Kádár, L. Hodinka, and A. Falus. 2000. Soluble interleukin-6 receptor in plasma and in lymphocyte culture supernatants of healthy individuals and patients with systemic lupus erythematosus and rheumatoid arthritis. Med. Sci. Monit. 6: 13-18.
79. Reinisch, W., C. Gasché, W. Tillinger, J. Wyatt, C. Lichtenberger, M. Willheim, C. Dejaco, T. Waldhör, S. Bakos, H. Vogelsang, et al. 1999. Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse. Am. J. Gastroenterol. 94: 2156-2164.
80. Buraczynska, M., L. Jozwiak, P. Ksiazek, E. Borowicz, and P. Mierzicki. 2007. Interleukin-6 gene polymorphism and faster progression to end-stage renal failure in chronic glomerulonephritis. Transi. Res. 150: 101-105.
81. Beffa, D. C, A. J. Fischman, S. P. Fagan, V F Hamrahi, K. W. Paul, M. Kaneki, Y M. Yu, R. G Tompkins, and E. A Carter. 2011. Simvastatin treatment improves survival in a murine model of burn sepsis: role of interleukin 6. Burns 37: 222-226.
82. Hagar, H. H., A. El-Medany, E. El-Eter, and M. Arafa. 2007. Ameliorative effect of pyrrolidinedithiocarbamate on acetic acid-induced colitis in rats. Eur. J. Pharmacol. 554: 69-77.
83. Itzkowitz, S. H. 2006. Molecular biology of dysplasia and cancer in inflammatory bowel disease. Gastroenterol. Clin. North Am. 35: 553-571.
84. Goldstein, J. L., F E. Silverstein, N. M. Agrawal, R. C. Hubbard, J. Kaiser, C. J. Maurath, K. M. Verbürg, and G. S. Geis. 2000. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am. J. Gastroenterol. 95: 1681-1690.
85. Zhang, D. K., L. N. Cheng, X. L. Huang, W. Shi, J. Y Xiang, and H. T Gan. 2009. Tetrandrine ameliorates dextran-sulfate-sodium-induced colitis in mice through inhibition of nuclear factor-κB activation. Int. J. Colorectal Dis. 24: 5-12.
86. Ivanenkov, Y A., K. V Balakin, and Y Lavrovsky. 2011. Small molecule inhibitors of NF-ΚB and JAK/STAT signal transduction pathways as promising anti-inflammatory therapeutics. Mini Rev. Med. Chem. 11: 55-78.